Beleid versterkt Takeda’s inzet voor best-in-class corporate governance verder

OSAKA, Japan– (BUSINESS WIRE) – Takeda Pharmaceutical Company Limited (TOKYO: 4502 / NYSE: TAK) (“Takeda”) kondigde vandaag aan dat de Raad van Bestuur een terugbetalingsbeleid voor bestuurders heeft goedgekeurd (“terugvorderingsbeleid”). De goedkeuring van het terugvorderingsbeleid maakt deel uit van Takeda’s voortdurende inspanningen om haar toewijding aan de beste corporate governance verder te versterken en is consistent met Takeda’s branchegenoten.

Het terugvorderingsbeleid bepaalt dat in het geval van een aanzienlijke herziening van de financiële resultaten of aanzienlijk wangedrag, de onafhankelijke externe leden van de Raad van Bestuur van Takeda Takeda kunnen verplichten om incentivevergoeding terug te verdienen. Dit omvat alle of een deel van de vergoeding die een lid van het Takeda Executive Team, een interne directeur van de Raad van Bestuur van Takeda en een ander individu dat door de onafhankelijke externe leden van de Raad van Bestuur van Takeda binnen het boekjaar is aangewezen, heeft ontvangen, en de drie (3) voorgaande boekjaren dat de noodzaak van een aanzienlijke herziening van de financiële resultaten of aanzienlijk wangedrag werd ontdekt.

Takeda Adopts Executive Compensation Recoupment Policy

Policy further strengthens Takeda’s commitment to best-in-class corporate governance

OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced that its Board of Directors approved an executive compensation recoupment policy (“clawback policy”). The adoption of the clawback policy is part of Takeda’s ongoing efforts to further strengthen its commitment to best-in-class corporate governance and is consistent with Takeda’s industry peers.

The clawback policy provides that in the event of a significant restatement of financial results or significant misconduct, the independent external members of Takeda’s Board of Directors may require Takeda to recoup incentive compensation. This would include all or a portion of the compensation received by any member of the Takeda Executive Team, any Internal Director on the Takeda’s Board of Directors, and any other individual designated by the independent external members of Takeda’s Board of Directors within the fiscal year, and the three (3) prior fiscal years, that the need for a significant restatement of financial results or significant misconduct was discovered.

The policy will take effect on April 1, 2020 and apply to short-term incentive compensation beginning with the Fiscal Year 2020 performance year and long-term incentive granted in Fiscal Year 2020 and continue to apply for all subsequent periods.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005913/en/

Contacts

Media Contacts:
Japanese Media

Kazumi Kobayashi

kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan

Tsuyoshi Tada

tsuyoshi.tada@takeda.com
+1 (617) 588-8849